Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012 Apr 20; 30(12):1371-7.
View in:
PubMed
subject areas
Administration, Oral
Administration, Oral
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Carcinoma, Renal Cell
Carcinoma, Renal Cell
Disease-Free Survival
Disease-Free Survival
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Administration Schedule
Female
Female
Humans
Humans
Indoles
Indoles
Kaplan-Meier Estimate
Kaplan-Meier Estimate
Kidney Neoplasms
Kidney Neoplasms
Male
Male
Maximum Tolerated Dose
Maximum Tolerated Dose
Middle Aged
Middle Aged
Neoplasm Staging
Neoplasm Staging
Prognosis
Prognosis
Proportional Hazards Models
Proportional Hazards Models
Pyrroles
Pyrroles
Risk Assessment
Risk Assessment
Survival Analysis
Survival Analysis
Treatment Outcome
Treatment Outcome
authors with profiles
Mark R Olsen